business
Goldman Sachs initiates Hemab Therapeutics stock with buy rating on rare disease drug potential
Goldman Sachs initiates Hemab Therapeutics stock with buy rating on rare disease drug potential
Read full story on Investing.com → More top stories
Aggregated and edited by the Scoop newsroom. We surface news from Investing.com alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop